Effects of high sucrose diet, gemfibrozil, and their combination on plasma paraoxonase 1 activity and lipid levels in rats. 2010

Marija Macan, and Nada Vrkić, and Ana Lucić Vrdoljak, and Božica Radić, and Vlasta Bradamante
University of Zagreb, School of Medicine, Department of Pharmacology, Zagreb, Croatia.

We investigated the influence of high sucrose diet (HSD) after 3 or 5 weeks of administration on paraoxonase 1 (PON1) activity in plasma of normolipidemic rats and the relationship between serum PON1 activity, triacylglycerides (TGs), HDL and total cholesterol vs. the control group of rats fed normal, control diet (CD). Because the data about the influence of gemfibrozil (GEM) on PON1 activity are controversial, we also investigated its effects (administration in the 4th and 5th week in rats on HSD and CD) on plasma PON1 activity and lipid levels in normolipidemic rats, and in rats with hypertriglyceridemia caused by HSD. Our results obtained in rats on HSD show a significant increase of plasma TGs levels by 47% (P<0.05) after 5 weeks of treatment, and PON1 activity by 32% and 23% (P<0.05) after 3 and 5 weeks, but without change in lipid levels vs. rats on CD. In the rats on CD and HSD, GEM caused a significant decrease of PON1 activity by 44% and 33%, while a significant decrease of TGs level by 38% (P<0.05) was measured only in rats on CD. The effects of GEM on total cholesterol, HDL and LDL in both groups of rats were typical for its action on lipoprotein metabolism. Because GEM in the rat liver stimulates proliferation of peroxisomes, β oxidation, and production of H₂O₂, it is possible that the oxidative stress induced by GEM damages hepatocytes and lowers the synthesis of PON1.

UI MeSH Term Description Entries
D008055 Lipids A generic term for fats and lipoids, the alcohol-ether-soluble constituents of protoplasm, which are insoluble in water. They comprise the fats, fatty oils, essential oils, waxes, phospholipids, glycolipids, sulfolipids, aminolipids, chromolipids (lipochromes), and fatty acids. (Grant & Hackh's Chemical Dictionary, 5th ed) Lipid
D008297 Male Males
D004789 Enzyme Activation Conversion of an inactive form of an enzyme to one possessing metabolic activity. It includes 1, activation by ions (activators); 2, activation by cofactors (coenzymes); and 3, conversion of an enzyme precursor (proenzyme or zymogen) to an active enzyme. Activation, Enzyme,Activations, Enzyme,Enzyme Activations
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000960 Hypolipidemic Agents Substances that lower the levels of certain LIPIDS in the BLOOD. They are used to treat HYPERLIPIDEMIAS. Antihyperlipidemic,Antilipemic,Antilipemic Agents,Antilipemic Drug,Hypolipidemic Agent,Hypolipidemic Drug,Antihyperlipemics,Antihyperlipidemics,Antilipemic Drugs,Antilipemics,Hypolipidemic Drugs,Agent, Hypolipidemic,Agents, Antilipemic,Agents, Hypolipidemic,Drug, Antilipemic,Drug, Hypolipidemic,Drugs, Antilipemic,Drugs, Hypolipidemic
D015248 Gemfibrozil A lipid-regulating agent that lowers elevated serum lipids primarily by decreasing serum triglycerides with a variable reduction in total cholesterol. Apo-Gemfibrozil,Ausgem,Bolutol,CI-719,Chem mart Gemfibrozil,DBL Gemfibrozil,Decrelip,Gemfi 1A Pharma,Gemfibrosil,Gemfibrozilo Bayvit,Gemfibrozilo Bexal,Gemfibrozilo Ur,Gemhexal,Gen-Gemfibrozil,GenRX Gemfibrozil,Healthsense Gemfibrozil,Jezil,Lipazil,Lipox Gemfi,Lipur,Litarek,Lopid,Lopid R,Novo-Gemfibrozil,Nu-Gemfibrozil,PMS-Gemfibrozil,Pilder,SBPA Gemfibrozil,Terry White Chemists Gemfibrozil,Trialmin,Apo Gemfibrozil,ApoGemfibrozil,Bayvit, Gemfibrozilo,CI 719,CI719,Gemfibrozil, GenRX,Gemfibrozil, Healthsense,Gemfibrozil, SBPA,Gen Gemfibrozil,GenGemfibrozil,Novo Gemfibrozil,Nu Gemfibrozil,NuGemfibrozil,PMS Gemfibrozil
D043303 Aryldialkylphosphatase An enzyme which catalyzes the hydrolysis of an aryl-dialkyl phosphate to form dialkyl phosphate and an aryl alcohol. It can hydrolyze a broad spectrum of organophosphate substrates and a number of aromatic carboxylic acid esters. It may also mediate an enzymatic protection of LOW DENSITY LIPOPROTEINS against oxidative modification and the consequent series of events leading to ATHEROMA formation. The enzyme was previously regarded to be identical with Arylesterase (EC 3.1.1.2). Aryl-dialkyl Phosphatase,Arylalkylphosphatase,Homocysteine Thiolactone Hydrolase,OPA Anhydrase,OPH Enzyme,Organophosphorus Acid Anhydrase,Organophosphorus Acid Anhydrolase,Organophosphorus Acid Hydrolase,Organophosphorus Hydrolase,Paraoxonase,Paraoxonase-1,Paraoxonase-2,Acid Anhydrase, Organophosphorus,Acid Anhydrolase, Organophosphorus,Acid Hydrolase, Organophosphorus,Anhydrase, OPA,Anhydrase, Organophosphorus Acid,Anhydrolase, Organophosphorus Acid,Aryl dialkyl Phosphatase,Enzyme, OPH,Hydrolase, Homocysteine Thiolactone,Hydrolase, Organophosphorus,Hydrolase, Organophosphorus Acid,Paraoxonase 1,Paraoxonase 2,Phosphatase, Aryl-dialkyl,Thiolactone Hydrolase, Homocysteine
D050356 Lipid Metabolism Physiological processes in biosynthesis (anabolism) and degradation (catabolism) of LIPIDS. Metabolism, Lipid
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus
D019422 Dietary Sucrose Sucrose present in the diet. It is added to food and drinks as a sweetener. Sucrose, Dietary,Table Sugar,Dietary Sucroses,Sucroses, Dietary,Sugars, Table,Table Sugars

Related Publications

Marija Macan, and Nada Vrkić, and Ana Lucić Vrdoljak, and Božica Radić, and Vlasta Bradamante
June 2011, Basic & clinical pharmacology & toxicology,
Marija Macan, and Nada Vrkić, and Ana Lucić Vrdoljak, and Božica Radić, and Vlasta Bradamante
August 1996, Journal of clinical pharmacology,
Marija Macan, and Nada Vrkić, and Ana Lucić Vrdoljak, and Božica Radić, and Vlasta Bradamante
December 1985, Metabolism: clinical and experimental,
Marija Macan, and Nada Vrkić, and Ana Lucić Vrdoljak, and Božica Radić, and Vlasta Bradamante
May 1979, Experientia,
Marija Macan, and Nada Vrkić, and Ana Lucić Vrdoljak, and Božica Radić, and Vlasta Bradamante
January 1996, Artery,
Marija Macan, and Nada Vrkić, and Ana Lucić Vrdoljak, and Božica Radić, and Vlasta Bradamante
July 1973, Lancet (London, England),
Marija Macan, and Nada Vrkić, and Ana Lucić Vrdoljak, and Božica Radić, and Vlasta Bradamante
November 2016, Chemico-biological interactions,
Marija Macan, and Nada Vrkić, and Ana Lucić Vrdoljak, and Božica Radić, and Vlasta Bradamante
April 1982, Atherosclerosis,
Marija Macan, and Nada Vrkić, and Ana Lucić Vrdoljak, and Božica Radić, and Vlasta Bradamante
January 2021, Clinical and experimental pharmacology & physiology,
Marija Macan, and Nada Vrkić, and Ana Lucić Vrdoljak, and Božica Radić, and Vlasta Bradamante
March 1981, The Journal of nutrition,
Copied contents to your clipboard!